- Home
- SCLX vs GROV Comparison
SCLX vs GROV Comparison
Compare SCLX & GROV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- GROV
- Stock Information
- Founded
- SCLX 2011
- GROV 2016
- Country
- SCLX United States
- GROV United States
- Employees
- SCLX N/A
- GROV N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- GROV Package Goods/Cosmetics
- Sector
- SCLX Health Care
- GROV Consumer Discretionary
- Exchange
- SCLX Nasdaq
- GROV Nasdaq
- Market Cap
- SCLX 51.3M
- GROV 59.0M
- IPO Year
- SCLX N/A
- GROV N/A
- Fundamental
- Price
- SCLX $0.23
- GROV $1.35
- Analyst Decision
- SCLX Strong Buy
- GROV Buy
- Analyst Count
- SCLX 4
- GROV 1
- Target Price
- SCLX $14.00
- GROV $2.00
- AVG Volume (30 Days)
- SCLX 1.1M
- GROV 82.2K
- Earning Date
- SCLX 05-12-2025
- GROV 03-11-2025
- Dividend Yield
- SCLX N/A
- GROV N/A
- EPS Growth
- SCLX N/A
- GROV N/A
- EPS
- SCLX N/A
- GROV N/A
- Revenue
- SCLX $55,152,000.00
- GROV $203,425,000.00
- Revenue This Year
- SCLX $24.19
- GROV $2.49
- Revenue Next Year
- SCLX $109.90
- GROV $7.66
- P/E Ratio
- SCLX N/A
- GROV N/A
- Revenue Growth
- SCLX 22.02
- GROV N/A
- 52 Week Low
- SCLX $0.21
- GROV $1.19
- 52 Week High
- SCLX $2.30
- GROV $1.95
- Technical
- Relative Strength Index (RSI)
- SCLX 36.43
- GROV 31.34
- Support Level
- SCLX $0.22
- GROV $1.34
- Resistance Level
- SCLX $0.29
- GROV $1.66
- Average True Range (ATR)
- SCLX 0.03
- GROV 0.08
- MACD
- SCLX -0.00
- GROV -0.03
- Stochastic Oscillator
- SCLX 25.59
- GROV 10.34
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products.